IA
SNNA

IFP Advisors’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

IFP Advisors’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-180,552
Closed -$2.74M – 4126
2018
Q2 		$2.74M Buy
+180,552
New +$3.06M 0.12% 200

Other funds holding SNNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.23B AUM 51.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

IFP Advisors's SNNA Position: Q3 2018 in Review

IFP Advisors sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q3 2018, closing a stake of 180,552 shares — an estimated $2.74M sold.

IFP Advisors first reported a position in SNNA in Q2 2018 and held it in 1 quarter. The position peaked at $2.74M in Q2 2018. 54 funds tracked by Wall St. Rank hold SNNA as of Q3 2018.

  • IFP Advisors reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • IFP Advisors sold 180,552 Sienna Biopharmaceuticals, Inc. shares in Q3 2018, an estimated $2.74M.
  • IFP Advisors first reported a position in Sienna Biopharmaceuticals, Inc. in Q2 2018 and held it in 1 quarter.
  • IFP Advisors's Sienna Biopharmaceuticals, Inc. position peaked at $2.74M in Q2 2018.
  • 54 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q3 2018.

Based on IFP Advisors's 13F filing for Q3 2018, filed 25 Oct 2018.